Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients

NCT07074457 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

CD30+ Peripheral T-cell Lymphoma

Interventions

DRUG: Induction therapy-3 cycles of BvC (Brentuximab vedotin plus Chidamide)
DRUG: Consolidation therapy- 3 or 6 cycles of BvC(Brentuximab vedotin plus chidamide)
DRUG: Maintenance therapy-chidamide

Sponsor

The First Affiliated Hospital of Soochow University